Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: Additional analyses from the AFFIRM randomized clinical trial

Annals of Oncology

Volumn 26, Issue 1, 2015, Pages 179-185

  Cella, David ^a   Ivanescu, C ^b   Holmstrom, S ^c   Bui, C N ^d   Spalding, J ^d   Fizazi, K ^e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b IQVIA   (United States)

^c Astellas Pharma Global Development   (Netherlands)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^e INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Health related quality of life; Metastatic castration resistant prostate cancer; Patient reported outcomes

Indexed keywords

DOCETAXEL; ENZALUTAMIDE; PLACEBO; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN; TAXOID;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FUNCTIONAL ASSESSMENT; HUMAN; INTENTION TO TREAT ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; MULTICENTER STUDY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; QUESTIONNAIRE; SELF REPORT; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; PHENYLTHIOHYDANTOIN; PLACEBOS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; QUALITY OF LIFE; SELF REPORT; SURVEYS AND QUESTIONNAIRES; TAXOIDS; TREATMENT OUTCOME;

EID: 84922548742     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu510     Document Type: Article

References (21)

1. Peeters P, Casamayor M, Moïse P et al. An assessment of patient-reported outcome (PRO) instruments used in prostate cancer (PCa) drug trials. 2011 European Multidisciplinary Meeting on Urological Cancers, Barcelona, Spain, 4-6 November.
2. FDA. Guidance for industry-patient-reported outcomes measures: use in medical product development to support labeling claims. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. (22 April 2014, date last accessed).
3. Basch E. Toward patient-centered drug development in oncology. N Engl J Med 2013; 369: 397-400.
4. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-1197.
5. Fizazi K, Scher HI, Miller K et al. Effect of enzalutamide on time to first skeletalrelated event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol 2014; 15: 1147-1156.
6. Esper P, Mo F, Chodak G et al. Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument. Urology 1997; 50: 920-928.
7. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
8. Cella D, Nichol MB, Eton D et al. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy-Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health 2009; 12: 124-129.
9. Yount S, Cella D, Banik D et al. Brief assessment of priority symptoms in hormone refractory prostate cancer: the FACT Advanced Prostate Symptom Index (FAPSI). Health Qual Life Outcomes 2003; 1: 69.
10. Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res 2002; 11: 207-221.
11. Yost KJ, Eton DT. Combining distribution-and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof 2005; 28: 172-191.
12. Mallinckrodt CH, Sanger TM, Dube S et al. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry 2003; 53: 754-760.
13. Molenberghs G, Kenward M. Missing Data in Clinical Studies. Chichester, UK: John Wiley & Sons Ltd, 2007.
14. Ratitch B, O'Kelly M, Tosiello R. Missing data in clinical trials: from clinical assumptions to statistical analysis using pattern mixture models. Pharm Stat 2013; 12: 337-347.
15. Thompson JC, Wood J, Feuer D. Prostate cancer: palliative care and pain relief. Br Med Bull 2007; 83: 341-354.
16. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-1764.
17. Kornblith AB, Herndon JE, Zuckerman E et al. The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study. Ann Oncol 2001; 12: 633-641.
18. Berthold DR, Pond GR, Roessner M et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostatespecific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008; 14: 2763-2767.
19. Basch E, Autio K, Ryan CJ et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol 2013; 14: 1193-1199.
20. Siddiqui O, Hung HM, O'Neill R. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat 2009; 19: 227-246.
21. Siddiqui O. MMRM versus MI in dealing with missing data-a comparison based on 25 NDA data sets. J Biopharm Stat 2011; 21: 423-436.